Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation

Autor: Michael Detmar, Stefan Ullmann, Bronislaw Pytowski, Kari Alitalo, Reto Huggenberger, Steven T. Proulx
Jazyk: angličtina
Rok vydání: 2010
Předmět:
Vascular Endothelial Growth Factor A
Angiogenesis
Immunology
Vascular Endothelial Growth Factor D
Dermatitis
Mice
Transgenic

Inflammation
610 Medicine & health
CD8-Positive T-Lymphocytes
Biology
Article
Mice
chemistry.chemical_compound
03 medical and health sciences
0302 clinical medicine
medicine
Animals
Immunology and Allergy
Lymphangiogenesis
Antibodies
Blocking

Skin
030304 developmental biology
0303 health sciences
integumentary system
Keratin-14
Kinase insert domain receptor
Cell Biology
Vascular Endothelial Growth Factor Receptor-3
Vascular Endothelial Growth Factor Receptor-2
3. Good health
Vascular endothelial growth factor
Vascular endothelial growth factor B
Lymphatic system
Vascular endothelial growth factor C
chemistry
030220 oncology & carcinogenesis
Chronic Disease
Cancer research
medicine.symptom
030215 immunology
Zdroj: Huggenberger, Reto; Ullmann, Stefan; Proulx, Steven T; Pytowski, Bronislaw; Alitalo, Kari; Detmar, Michael (2010). Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. The Journal of experimental medicine, 207(10), pp. 2255-2269. Rockefeller Univ. Press 10.1084/jem.20100559
The Journal of Experimental Medicine
Popis: The role of lymphangiogenesis in inflammation has remained unclear. To investigate the role of lymphatic versus blood vasculature in chronic skin inflammation, we inhibited vascular endothelial growth factor (VEGF) receptor (VEGFR) signaling by function-blocking antibodies in the established keratin 14 (K14)–VEGF-A transgenic (Tg) mouse model of chronic cutaneous inflammation. Although treatment with an anti–VEGFR-2 antibody inhibited skin inflammation, epidermal hyperplasia, inflammatory infiltration, and angiogenesis, systemic inhibition of VEGFR-3, surprisingly, increased inflammatory edema formation and inflammatory cell accumulation despite inhibition of lymphangiogenesis. Importantly, chronic Tg delivery of the lymphangiogenic factor VEGF-C to the skin of K14-VEGF-A mice completely inhibited development of chronic skin inflammation, epidermal hyperplasia and abnormal differentiation, and accumulation of CD8 T cells. Similar results were found after Tg delivery of mouse VEGF-D that only activates VEGFR-3 but not VEGFR-2. Moreover, intracutaneous injection of recombinant VEGF-C156S, which only activates VEGFR-3, significantly reduced inflammation. Although lymphatic drainage was inhibited in chronic skin inflammation, it was enhanced by Tg VEGF-C delivery. Together, these results reveal an unanticipated active role of lymphatic vessels in controlling chronic inflammation. Stimulation of functional lymphangiogenesis via VEGFR-3, in addition to antiangiogenic therapy, might therefore serve as a novel strategy to treat chronic inflammatory disorders of the skin and possibly also other organs.
Databáze: OpenAIRE